MG
KRYS icon

Michael Gelband’s Krystal Biotech KRYS Stock Holding History

Michael Gelband’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,952
Closed -$1.79M – 1733
2025
Q1 		$1.79M Buy
9,952
+191
+2% +$32.1K 0.02% 726
2024
Q4 		$1.53M Buy
+9,761
New +$1.73M 0.01% 815
2024
Q3 		– Sell
-14,892
Closed -$2.73M – 1861
2024
Q2 		$2.73M Sell
14,892
-3,380
-18% -$567K 0.02% 667
2024
Q1 		$3.25M Sell
18,272
-24,230
-57% -$3.37M 0.02% 532
2023
Q4 		$5.27M Buy
42,502
+14,752
+53% +$1.64M 0.03% 331
2023
Q3 		$3.22M Buy
27,750
+3,649
+15% +$445K 0.03% 501
2023
Q2 		$2.83M Sell
24,101
-112,040
-82% -$11.4M 0.02% 673
2023
Q1 		$10.9M Buy
136,141
+30,380
+29% +$2.39M 0.09% 253
2022
Q4 		$8.38M Buy
105,761
+40,975
+63% +$3.04M 0.12% 213
2022
Q3 		$4.52M Buy
64,786
+43,720
+208% +$3.16M 0.06% 440
2022
Q2 		$1.38M Buy
+21,066
New +$1.31M 0.02% 943
2019
Q2 		– Sell
-17,648
Closed -$581K – 1232
2019
Q1 		$581K Buy
+17,648
New +$416K 0.04% 290

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Michael Gelband's KRYS Position: Q2 2025 in Review

Michael Gelband sold out of Krystal Biotech (KRYS) in Q2 2025, closing a stake of 9,952 shares — an estimated $1.79M sold.

Michael Gelband first reported a position in KRYS in Q1 2019 and held it in 12 quarters. The position peaked at $10.9M in Q1 2023. 275 funds tracked by Wall St. Rank hold KRYS as of Q2 2025.

  • Michael Gelband reported no remaining Krystal Biotech position as of Q2 2025 after selling out during the quarter.
  • Michael Gelband sold 9,952 Krystal Biotech shares in Q2 2025, an estimated $1.79M.
  • Michael Gelband first reported a position in Krystal Biotech in Q1 2019 and held it in 12 quarters.
  • Michael Gelband's Krystal Biotech position peaked at $10.9M in Q1 2023.
  • 275 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.